cytarabine and mln 8237

cytarabine has been researched along with mln 8237 in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Carew, JS; Ecsedy, J; Espitia, CM; Giles, FJ; Kelly, KR; Nawrocki, ST; Padmanabhan, S; Yang, JJ; Zhang, M	1
Amrein, PC; Attar, EC; Ballen, KK; Bergeron, M; Blonquist, TM; Brunner, AM; Burke, M; Chen, YB; Connolly, C; Fathi, AT; Fishman, KM; Foster, J; Graubert, TA; Hermance, NM; Hobbs, G; Joseph, C; Manning, AL; McGregor, KL; Neuberg, DS; Perry, AM; Ramos, AY; Sadrzadeh, H; Silver, R; Som, TT; Supko, J; Wander, SA	1

Trials

1 trial(s) available for cytarabine and mln 8237

Article	Year
Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia. Haematologica, 2017, Volume: 102, Issue:4 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aurora Kinase A; Azepines; Cytarabine; Female; Humans; Idarubicin; Immunohistochemistry; Leukemia, Myeloid, Acute; Male; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Survival Analysis; Treatment Outcome	2017

Article

Year

Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia.

Haematologica, 2017, Volume: 102, Issue:4

Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aurora Kinase A; Azepines; Cytarabine; Female; Humans; Idarubicin; Immunohistochemistry; Leukemia, Myeloid, Acute; Male; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Survival Analysis; Treatment Outcome

2017

Other Studies

1 other study(ies) available for cytarabine and mln 8237

Article	Year
Targeting Aurora A kinase activity with the investigational agent alisertib increases the efficacy of cytarabine through a FOXO-dependent mechanism. International journal of cancer, 2012, Dec-01, Volume: 131, Issue:11 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Aurora Kinase A; Aurora Kinases; Azepines; Bcl-2-Like Protein 11; Cell Cycle; Cell Line, Tumor; Cell Survival; Cyclin-Dependent Kinase Inhibitor p27; Cytarabine; Drug Synergism; Female; Forkhead Box Protein O3; Forkhead Transcription Factors; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Membrane Proteins; Mice; Mice, SCID; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pyrimidines; Xenograft Model Antitumor Assays	2012

Article

Year

Targeting Aurora A kinase activity with the investigational agent alisertib increases the efficacy of cytarabine through a FOXO-dependent mechanism.

International journal of cancer, 2012, Dec-01, Volume: 131, Issue:11

Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Aurora Kinase A; Aurora Kinases; Azepines; Bcl-2-Like Protein 11; Cell Cycle; Cell Line, Tumor; Cell Survival; Cyclin-Dependent Kinase Inhibitor p27; Cytarabine; Drug Synergism; Female; Forkhead Box Protein O3; Forkhead Transcription Factors; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Membrane Proteins; Mice; Mice, SCID; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pyrimidines; Xenograft Model Antitumor Assays

2012